Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic

• HCQ, well known in rheumatology, dermatology and tropical medicine is now considered in the treatment and prophylaxy for the SARS-CoVid19. • Mental and neurological manifestations should be assessed following the use of hydrochloroquine particularly following prophylactic use. • For acute malaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Emmanuel, Stip, Östlundh, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305495/
https://www.ncbi.nlm.nih.gov/pubmed/32603983
http://dx.doi.org/10.1016/j.ajp.2020.102203
_version_ 1783548473190121472
author Emmanuel, Stip
Östlundh, Linda
author_facet Emmanuel, Stip
Östlundh, Linda
author_sort Emmanuel, Stip
collection PubMed
description • HCQ, well known in rheumatology, dermatology and tropical medicine is now considered in the treatment and prophylaxy for the SARS-CoVid19. • Mental and neurological manifestations should be assessed following the use of hydrochloroquine particularly following prophylactic use. • For acute malaria studies, HCQ was associated with high prevalenceof mental neurological manifestations amongst anti-malaria drugs. • Recommendations of using HCQ in COVID are variable and sometimes contradictory depending on agencies and countries.
format Online
Article
Text
id pubmed-7305495
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-73054952020-06-22 Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic Emmanuel, Stip Östlundh, Linda Asian J Psychiatr Letter to the Editor • HCQ, well known in rheumatology, dermatology and tropical medicine is now considered in the treatment and prophylaxy for the SARS-CoVid19. • Mental and neurological manifestations should be assessed following the use of hydrochloroquine particularly following prophylactic use. • For acute malaria studies, HCQ was associated with high prevalenceof mental neurological manifestations amongst anti-malaria drugs. • Recommendations of using HCQ in COVID are variable and sometimes contradictory depending on agencies and countries. Elsevier B.V. 2020-12 2020-06-20 /pmc/articles/PMC7305495/ /pubmed/32603983 http://dx.doi.org/10.1016/j.ajp.2020.102203 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Emmanuel, Stip
Östlundh, Linda
Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
title Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
title_full Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
title_fullStr Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
title_full_unstemmed Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
title_short Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
title_sort psychiatric adverse events with hydroxychloroquine during covid-19 pandemic
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305495/
https://www.ncbi.nlm.nih.gov/pubmed/32603983
http://dx.doi.org/10.1016/j.ajp.2020.102203
work_keys_str_mv AT emmanuelstip psychiatricadverseeventswithhydroxychloroquineduringcovid19pandemic
AT ostlundhlinda psychiatricadverseeventswithhydroxychloroquineduringcovid19pandemic

Ejemplares similares